Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › AZD5004 (ECC5004)

AZD5004 (ECC5004)

GLP-1 (small molecule) · oral · AstraZeneca (Eccogene)

Data cut 12 November 2026 · page built 16 November 2026 · 11 trial arms · 2 trials with results · 9 registered trials · see on the pipeline board

Summary

Also known as
Eccogene → AstraZeneca
Mechanism
GLP-1 (small molecule)
Route
oral
Company
AstraZeneca (Eccogene)
Highest development stage
phase 3
Status (as of data cut)
Elecoglipron. Phase 2b VISTA (obesity) and SOLSTICE (T2D) positive; phase 3 started (June 2026) verify
Next milestone
Phase 3 readouts

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity2 phase 3 ongoingPhase 2b VISTA positive; phase 3 started June 2026Phase 3
T2D2 phase 3 ongoingPhase 2b SOLSTICE positive; phase 3 ongoing
CV outcomes0 no data
CKD0 no data
HFpEF0 no data
MASH0 no data
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
SOLSTICE (NCT06579105)5 mg QD vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3t2d26406−2.9 % vs −1.7 %
Δ −1.2 pp
—−0.9 vs −0.1——————press release
SOLSTICE (NCT06579105)15 mg QD vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3t2d26406−3.4 % vs −1.7 %
Δ −1.7 pp
—−1.1 vs −0.1——————press release
SOLSTICE (NCT06579105)25 mg QD vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3t2d26406−4.0 % vs −1.7 %
Δ −2.3 pp
—−1.2 vs −0.1——————press release
SOLSTICE (NCT06579105)50 mg QD (escalated every 2 weeks) vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3t2d26406−5.9 % vs −1.7 %
Δ −4.2 pp
—−1.4 vs −0.1——————press release
SOLSTICE (NCT06579105)75 mg QD (escalated every 2 weeks) vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3t2d26406−7.7 % vs −1.7 %
Δ −6.0 pp
—−1.9 vs −0.1——37.0 vs 3.018.0 vs 1.0——press release
SOLSTICE (NCT06579105)75 mg QD (escalated every 4 weeks) vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3t2d26406−7.0 % vs −1.7 %
Δ −5.3 pp
—−1.6 vs −0.1——————press release
VISTA (NCT06579092)5 mg QDobesity36310−2.7 % vs −0.6 %
Δ −2.1 pp
————————press release
VISTA (NCT06579092)15 mg QDobesity36310−6.5 % vs −0.6 %
Δ −5.9 pp
————————press release
VISTA (NCT06579092)50 mg QD (escalated every 4 weeks)obesity36310−9.2 % vs −0.6 %
Δ −8.6 pp
————————press release
VISTA (NCT06579092)75 mg QD (escalated weekly)obesity36310−11.8 % vs −0.6 %
Δ −11.2 pp
————————press release
VISTA (NCT06579092)75 mg QD (escalated every 2 weeks)obesity36310−11.1 % vs −0.6 %
Δ −10.5 pp
————————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (19)
  • 5 mg QD · weight_eff · press release
    Week 36 | -2.7% | -6.5% | -9.2% | -11.8% | -11.1% | -0.3%
  • 15 mg QD · weight_eff · press release
    Week 36 | -2.7% | -6.5% | -9.2% | -11.8% | -11.1% | -0.3%
  • 50 mg QD (escalated every 4 weeks) · weight_eff · press release
    Week 36 | -2.7% | -6.5% | -9.2% | -11.8% | -11.1% | -0.3%
  • 75 mg QD (escalated weekly) · weight_eff · press release
    Week 36 | -2.7% | -6.5% | -9.2% | -11.8% | -11.1% | -0.3%
  • 75 mg QD (escalated every 2 weeks) · weight_eff · press release
    Week 36 | -2.7% | -6.5% | -9.2% | -11.8% | -11.1% | -0.3%
  • 5 mg QD · hba1c · publication (abstract)
    change from baseline in HbA1c ranged between -0·91% (95% CI -1·25 to -0·58; 5 mg elecoglipron)
  • 5 mg QD · weight_eff · press release
    | -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%
  • 15 mg QD · hba1c · press release
    | -0.9% | -1.1% | -1.2 | -1.4% | -1.9% | -1.6% | -0.2% | -1.3%
  • 15 mg QD · weight_eff · press release
    | -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%
  • 25 mg QD · hba1c · press release
    | -0.9% | -1.1% | -1.2 | -1.4% | -1.9% | -1.6% | -0.2% | -1.3%
  • 25 mg QD · weight_eff · press release
    | -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%
  • 50 mg QD (escalated every 2 weeks) · hba1c · press release
    | -0.9% | -1.1% | -1.2 | -1.4% | -1.9% | -1.6% | -0.2% | -1.3%
  • 50 mg QD (escalated every 2 weeks) · weight_eff · press release
    | -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%
  • 75 mg QD (escalated every 2 weeks) · hba1c · publication (abstract)
    -1·88% (-2·23 to -1·53; 75 mg elecoglipron with every 2-week dose-escalation step) compared with -0·15% (-0·42 to 0·12) with placebo
  • 75 mg QD (escalated every 2 weeks) · weight_eff · press release
    | -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%
  • 75 mg QD (escalated every 2 weeks) · nausea · press release, safety paragraph (SOLSTICE)
    In SOLSTICE, the most common adverse events with elecoglipron (75mg) compared to placebo were nausea (37%, 3%), constipation (29%, 4%), diarrhoea (21%, 15%) and vomiting (18%, 1%)
  • 75 mg QD (escalated every 2 weeks) · vomiting · press release, safety paragraph (SOLSTICE)
    In SOLSTICE, the most common adverse events with elecoglipron (75mg) compared to placebo were nausea (37%, 3%), constipation (29%, 4%), diarrhoea (21%, 15%) and vomiting (18%, 1%)
  • 75 mg QD (escalated every 4 weeks) · hba1c · press release
    | -0.9% | -1.1% | -1.2 | -1.4% | -1.9% | -1.6% | -0.2% | -1.3%
  • 75 mg QD (escalated every 4 weeks) · weight_eff · press release
    | -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%

Registered trials (9)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
Elevate-CKD
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
CKDPhase 3recruiting2026-08 → 2030-107000recruitingNCT07753993
Elevate-HF
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
CV outcomesPhase 3recruiting2026-08 → 2029-096950recruitingNCT07761117
Elecoglipron
A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus
ObesityPhase 3recruiting2026-08 → 2028-04351recruitingNCT07775404
Eluminate-1
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
T2DPhase 3recruiting2026-07 → 2028-07800recruitingNCT07662044
Eluminate-5
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
T2DPhase 3recruiting2026-07 → 2028-072000recruitingNCT07662109
Eluminate-4
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
T2DPhase 3recruiting2026-07 → 2028-07900recruitingNCT07662135
Eluminate-2
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
T2DPhase 3recruiting2026-07 → 2028-051200recruitingNCT07662213
Eluminate-3
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
T2DPhase 3recruiting2026-07 → 2028-05600recruitingNCT07664553
Embold
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
ObesityPhase 3recruiting2026-06 → 2028-074500recruitingNCT07667803

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: AZD5004 (ECC5004). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/azd5004/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.